Table 1 Current microfluidic technologies for drug screening.
From: Drug screening of cancer cell lines and human primary tumors using droplet microfluidics
Sample type | Subject | Total sampled conditions | Technology | Reference |
|---|---|---|---|---|
Protein | Enzyme | 704 | Droplet microfluidics | |
Cell line | Cells in agarose | 23 × 23 = 529 | Array printing | |
Cells | 3328 | Nano-well patterning | ||
Bacteria | 20 | Flow microfluidics | ||
Suspended and adherent cells | 2 channels of 5 conditions | Droplet microfluidics | This study | |
Primary tumor | Leukemia cells | 1266 | Plate reader assay# | |
Lung cancer and stromal cells | 3 | Flow microfluidics | ||
Multiple myeloma cells | 1 drug × <5 dose | Flow microfluidics | ||
T2 breast tumor | 16 | Implanted chip | ||
Primary tumor dissociated cells | 5–10 conditions depending on cell number | Droplet microfluidics | This study | |
Cultured tumor/CTC | Cultured CTC | 38 × 6 = 228 | Ex vivo culture | |
Cultured single CTC | Dependent on cell amplification | Trap and release → in vitro culture |
